Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19
Administering N-acetylcysteine (NAC) could counteract the effect of free radicals, improving the clinical evolution of patients admitted to the Intensive Care Unit (ICU). This study aimed to investigate the clinical and biochemical effects of administering NAC to critically ill patients with COVID-1...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/9/2235 |
| _version_ | 1797601913836929024 |
|---|---|
| author | Yenifer Gamarra-Morales Lourdes Herrera-Quintana Jorge Molina-López Héctor Vázquez-Lorente Juan Francisco Machado-Casas José Castaño-Pérez José Miguel Pérez-Villares Elena Planells |
| author_facet | Yenifer Gamarra-Morales Lourdes Herrera-Quintana Jorge Molina-López Héctor Vázquez-Lorente Juan Francisco Machado-Casas José Castaño-Pérez José Miguel Pérez-Villares Elena Planells |
| author_sort | Yenifer Gamarra-Morales |
| collection | DOAJ |
| description | Administering N-acetylcysteine (NAC) could counteract the effect of free radicals, improving the clinical evolution of patients admitted to the Intensive Care Unit (ICU). This study aimed to investigate the clinical and biochemical effects of administering NAC to critically ill patients with COVID-19. A randomized controlled clinical trial was conducted on ICU patients (<i>n =</i> 140) with COVID-19 and divided into two groups: patients treated with NAC (NAC-treated group) and patients without NAC treatment (control group). NAC was administered as a continuous infusion with a loading dose and a maintenance dose during the study period (from admission until the third day of ICU stay). NAC-treated patients showed higher PaO<sub>2</sub>/FiO<sub>2</sub> (<i>p ≤</i> 0.014) after 3 days in ICU than their control group counterparts. Moreover, C-reactive protein (<i>p ≤</i> 0.001), D-dimer (<i>p ≤</i> 0.042), and lactate dehydrogenase (<i>p ≤</i> 0.001) levels decreased on the third day in NAC-treated patients. Glutathione concentrations decreased in both NAC-treated (<i>p ≤</i> 0.004) and control (<i>p ≤</i> 0.047) groups after 3 days in ICU; whereas glutathione peroxidase did not change during the ICU stay. The administration of NAC manages to improve the clinical and analytical response of seriously ill patients with COVID-19 compared to the control group. NAC is able to stop the decrease in glutathione concentrations. |
| first_indexed | 2024-03-11T04:09:56Z |
| format | Article |
| id | doaj.art-3af7441b8a384aeda1f106a54497e5b2 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-11T04:09:56Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-3af7441b8a384aeda1f106a54497e5b22023-11-17T23:30:58ZengMDPI AGNutrients2072-66432023-05-01159223510.3390/nu15092235Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19Yenifer Gamarra-Morales0Lourdes Herrera-Quintana1Jorge Molina-López2Héctor Vázquez-Lorente3Juan Francisco Machado-Casas4José Castaño-Pérez5José Miguel Pérez-Villares6Elena Planells7Clinical Analysis Unit, Valle de los Pedroches Hospital, Pozoblanco, 14400 Córdoba, SpainDepartment of Physiology, School of Pharmacy, Institute of Nutrition and Food Technology “José Mataix”, University of Granada, 18071 Granada, SpainFaculty of Education, Psychology and Sports Sciences, University of Huelva, 21007 Huelva, SpainDepartment of Physiology, School of Pharmacy, Institute of Nutrition and Food Technology “José Mataix”, University of Granada, 18071 Granada, SpainIntensive Care Unit, Virgen de las Nieves Hospital, Fuerzas Armadas Avenue, 18014 Granada, SpainIntensive Care Unit, Virgen de las Nieves Hospital, Fuerzas Armadas Avenue, 18014 Granada, SpainIntensive Care Unit, Virgen de las Nieves Hospital, Fuerzas Armadas Avenue, 18014 Granada, SpainDepartment of Physiology, School of Pharmacy, Institute of Nutrition and Food Technology “José Mataix”, University of Granada, 18071 Granada, SpainAdministering N-acetylcysteine (NAC) could counteract the effect of free radicals, improving the clinical evolution of patients admitted to the Intensive Care Unit (ICU). This study aimed to investigate the clinical and biochemical effects of administering NAC to critically ill patients with COVID-19. A randomized controlled clinical trial was conducted on ICU patients (<i>n =</i> 140) with COVID-19 and divided into two groups: patients treated with NAC (NAC-treated group) and patients without NAC treatment (control group). NAC was administered as a continuous infusion with a loading dose and a maintenance dose during the study period (from admission until the third day of ICU stay). NAC-treated patients showed higher PaO<sub>2</sub>/FiO<sub>2</sub> (<i>p ≤</i> 0.014) after 3 days in ICU than their control group counterparts. Moreover, C-reactive protein (<i>p ≤</i> 0.001), D-dimer (<i>p ≤</i> 0.042), and lactate dehydrogenase (<i>p ≤</i> 0.001) levels decreased on the third day in NAC-treated patients. Glutathione concentrations decreased in both NAC-treated (<i>p ≤</i> 0.004) and control (<i>p ≤</i> 0.047) groups after 3 days in ICU; whereas glutathione peroxidase did not change during the ICU stay. The administration of NAC manages to improve the clinical and analytical response of seriously ill patients with COVID-19 compared to the control group. NAC is able to stop the decrease in glutathione concentrations.https://www.mdpi.com/2072-6643/15/9/2235COVID-19N-acetylcysteinemortalityantioxidantpneumoniabiomarker |
| spellingShingle | Yenifer Gamarra-Morales Lourdes Herrera-Quintana Jorge Molina-López Héctor Vázquez-Lorente Juan Francisco Machado-Casas José Castaño-Pérez José Miguel Pérez-Villares Elena Planells Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19 Nutrients COVID-19 N-acetylcysteine mortality antioxidant pneumonia biomarker |
| title | Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19 |
| title_full | Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19 |
| title_fullStr | Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19 |
| title_full_unstemmed | Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19 |
| title_short | Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19 |
| title_sort | response to intravenous n acetylcysteine supplementation in critically ill patients with covid 19 |
| topic | COVID-19 N-acetylcysteine mortality antioxidant pneumonia biomarker |
| url | https://www.mdpi.com/2072-6643/15/9/2235 |
| work_keys_str_mv | AT yenifergamarramorales responsetointravenousnacetylcysteinesupplementationincriticallyillpatientswithcovid19 AT lourdesherreraquintana responsetointravenousnacetylcysteinesupplementationincriticallyillpatientswithcovid19 AT jorgemolinalopez responsetointravenousnacetylcysteinesupplementationincriticallyillpatientswithcovid19 AT hectorvazquezlorente responsetointravenousnacetylcysteinesupplementationincriticallyillpatientswithcovid19 AT juanfranciscomachadocasas responsetointravenousnacetylcysteinesupplementationincriticallyillpatientswithcovid19 AT josecastanoperez responsetointravenousnacetylcysteinesupplementationincriticallyillpatientswithcovid19 AT josemiguelperezvillares responsetointravenousnacetylcysteinesupplementationincriticallyillpatientswithcovid19 AT elenaplanells responsetointravenousnacetylcysteinesupplementationincriticallyillpatientswithcovid19 |